生物治疗儿童喘的方法
Antonio Nieto-García1, María Nieto-Cid2, Ángel Mazón-Ramos3
1Health Research Institute La Fe, Valencia.
Current opinion in allergy and clinical immunology
|April 3, 2024
概括
生物学家提供了一种革命性的方法来治疗严重的儿科喘,但仔细的选择至关重要. 虽然有五种生物药物获得批准,但长期安全数据有限,奥马利祖马布在儿童中显示出最强有力的证据.
科学领域:
- 儿科肺病学 儿科肺病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在儿童中,严重的喘是一个重大的治疗挑战.
- 生物药物代表着向严重喘的个性化药物转向的范式转变.
- 五种生物药物 (奥马利祖马布,梅波利祖马布,本拉利祖马布,杜皮卢马布,特泽佩卢马布) 已被批准用于儿科.
研究的目的:
- 为儿童严重喘的生物药物提供最新的概述.
- 为了指导适当的选择和处方的生物药物.
- 突出目前在生物治疗中的辩论和考虑.
主要方法:
- 关于严重儿科喘的生物疗法现有文献的综述.
- 分析已批准的生物制剂,它们的疗效和安全性.
- 讨论证据缺口和未来的研究方向.
主要成果:
- 生物药物已经改变了严重喘的治疗方法,使得个性化治疗方法成为可能.
- 虽然有效,但选择最佳的生物药物需要仔细考虑.
- 目前,奥马利祖马布在儿童中拥有最广泛的中长期疗效和安全性数据.
结论:
- 生物制剂的使用有助于在儿童严重喘中转向个性化医疗.
- 由于数据不尽相同,选择最合适的生物药物仍然是一个关键的挑战.
- 需要进行进一步的研究,以解决新生物制剂的中长期安全性和有效性数据.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
288
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
288
Asthma: Pathogenesis and Management
394
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
394
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Antiasthma Drugs: Leukotriene Modifiers
291
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
291


